Can Most-Favored Nation (MFN) Pricing Deliver on Cost Savings Promise?

Leeann Lui, VP, Market Access Strategy at Lumanity, was recently featured in a three-part APM Market Access article series unpacking the purported cost savings tied to most-favored nation (MFN) pricing in the US. While headline savings figures depend heavily on a number of long-term assumptions, the reality is much less clear for manufacturers.

The articles are available now for current APM Market Access subscribers:

• Experts question assumptions made by White House on savings potential on MFN prices for existing drugs on Medicaid
• US Reference pricing here to stay, but questions remain on codifying MFN into law
• White House estimates on MFN savings potential under scrutiny